Tags

Type your tag names separated by a space and hit enter

[Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system].
J Pharm Belg. 2005; 60(3):89-91.JP

Abstract

The endocannabinoid system plays a major role in the regulation of body energy by stimulation of the appetite in the hypothalamus and increase of fat accumulation in adipocytes. The blockade of the cannabinoid system (CB1) by the specific inhibitor (rimonabant) decreases food intake and adiposity in animals and in humans. Moreover rimonabant lowers tobacco addiction. Clinical studies (RIO-LIPIDS and RIO-EUROPE) have recently confirmed that rimonabant combined with a hypocaloric diet over 1 year, promoted significant decrease of body weight, waist circumference and improvement of dyslipidemia. Rimonabant was well tolerated with mild and transient side effects. The future place of rimonabant in the strategy of obesity is still to be clarified.

Authors+Show Affiliations

Service de Médecine, C.H.U. Tivoli, La Louvière, U.L.B.No affiliation info available

Pub Type(s)

Journal Article
Review

Language

fre

PubMed ID

16252510

Citation

Ducobu, J, and J Sternon. "[Rimonabant (Acomplia), Specific Inhibitor of the Endocannabinoid System]." Journal De Pharmacie De Belgique, vol. 60, no. 3, 2005, pp. 89-91.
Ducobu J, Sternon J. [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system]. J Pharm Belg. 2005;60(3):89-91.
Ducobu, J., & Sternon, J. (2005). [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system]. Journal De Pharmacie De Belgique, 60(3), 89-91.
Ducobu J, Sternon J. [Rimonabant (Acomplia), Specific Inhibitor of the Endocannabinoid System]. J Pharm Belg. 2005;60(3):89-91. PubMed PMID: 16252510.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Rimonabant (Acomplia), specific inhibitor of the endocannabinoid system]. AU - Ducobu,J, AU - Sternon,J, PY - 2005/10/29/pubmed PY - 2005/12/13/medline PY - 2005/10/29/entrez SP - 89 EP - 91 JF - Journal de pharmacie de Belgique JO - J Pharm Belg VL - 60 IS - 3 N2 - The endocannabinoid system plays a major role in the regulation of body energy by stimulation of the appetite in the hypothalamus and increase of fat accumulation in adipocytes. The blockade of the cannabinoid system (CB1) by the specific inhibitor (rimonabant) decreases food intake and adiposity in animals and in humans. Moreover rimonabant lowers tobacco addiction. Clinical studies (RIO-LIPIDS and RIO-EUROPE) have recently confirmed that rimonabant combined with a hypocaloric diet over 1 year, promoted significant decrease of body weight, waist circumference and improvement of dyslipidemia. Rimonabant was well tolerated with mild and transient side effects. The future place of rimonabant in the strategy of obesity is still to be clarified. SN - 0047-2166 UR - https://www.unboundmedicine.com/medline/citation/16252510/[Rimonabant__Acomplia__specific_inhibitor_of_the_endocannabinoid_system]_ DB - PRIME DP - Unbound Medicine ER -